Digital Tools Provide Insight into AFib

Atrial fibrillation (AFib) is one of the most common heart rhythm disorders, but researchers still don’t have a reliable way to predict who will develop it or when. Unlike conditions such as coronary disease, where biomarkers like high cholesterol provide early warning signs and treatment options, AFib lacks a definitive predictor.

Sept. 2, 2025 — Although cardiovascular disease is a leading cause of death for women, they remain underrepresented in clinical trials for common heart conditions. These findings, by investigators in the Smidt Heart Institute at Cedars-Sinai, were presented at the 2025 European Society of Cardiology Congress in Madrid.

Sept. 9, 2025 — The John Ritter Foundation for Aortic Health, a nonprofit dedicated to raising awareness, advancing research and providing education on thoracic aortic disease to prevent premature deaths, has released an updated Ritter Rules, a set of clear guidelines designed to promote early detection, empower patients, and improve outcomes.

Sept. 9, 2025 — The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, the PERT Consortium and Society for Vascular Medicine (SVM) have come together to form the Get Out the Clot campaign. The groups have announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care (blood clots).

Sept. 2, 2025 — GE HealthCare recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Revolution Vibe CT system, an innovative imaging solution designed to elevate coronary CT angiography (CCTA). With Unlimited One-Beat Cardiac imaging and integrated AI-powered tools, Revolution Vibe offers clinicians a fast, powerful, and non-invasive way to identify potential heart blockages while enhancing patient comfort and streamlining workflow.

Sept. 04, 2025 — CorVista Health has published a new case series in the Journal of the American College of Cardiology (JACC), showcasing real-world clinical applications of the CorVista System, a non-invasive, point-of-care diagnostic test for pulmonary hypertension (PH).

Sept. 9, 2025 — Neurescue ApS has received CE Mark approval for its Neurescue device, a medical device approved to treat non-shockable cardiac arrest. Granted by TÜV SÜD after an expedited six-month review under Europe’s Medical Device Regulation (MDR), this milestone marks one of the most significant advances in resuscitation since the introduction of CPR in 1960.

Sept. 8, 2025 — GE HealthCare recently announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S.

Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation (AF).

Sept. 8, 2025  — AMO Pharma Ltd., a clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, has announced a license agreement with Population Health Research Institute (PHRI), a joint global health research institute of McMaster University and Hamilton Health Sciences, and Venca Research Inc. The agreement will support the development and potential manufacturing, and commercialization of AMO-02 in arrhythmogenic right ventricular cardiomyopathy (ARVC).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now